Nodthera's IPO
Filed Oct 21, 2026 (Form S-1). No terms yet. Applied to list on Nasdaq as RZRA.
Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.
Once Nodthera lists, Breakaway scores it against every US stock
- Its Quality Score from its second session, ranked against 3,191 stocks
- Every insider trade, the day it is filed
- The lock-up's end on your calendar, once the prospectus dates it
- An alert when its score is first set, and when it turns
See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.
What does Nodthera do?
“We are a clinical-stage biotechnology company developing a portfolio of internally invented, proprietary and wholly-owned oral inhibitors of NOD-like receptor protein 3, or NLRP3.”
| Fact | Nodthera |
|---|---|
| Incorporated | Delaware, 2021 |
| Employees | 21 full-time, as of September 30, 2026 |
| Website | rezera.com |
What is the offering?
Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.
| Fact | Nodthera |
|---|---|
| Underwriters | Jefferies, TD Cowen, Cantor, and Wedbush |
| Exchange | Nasdaq, as RZRA (applied to list) |
What the filing says about its money
| Fact | Nodthera |
|---|---|
| Revenue | None from product sales yet |
| Cash | $3.9 million, as of June 30, 2026 |
| Last preferred stock | Series C preferred |
| Raised before the IPO | $200 million in private financings |
What risks does Nodthera name first?
- “We are a biotechnology company with a limited operating history and have not generated any revenue to date from drug sales, and may never become profitable.”
- “We have incurred significant operating losses since our inception and anticipate that we will incur continued losses for the foreseeable future.”
- “As part of our ongoing business, we will need to raise substantial additional funding beyond our current capital.”
Every date of Nodthera's IPO
| What | Day |
|---|---|
| Registration filed | Oct 21, 2026 |
| Lock-up | 180 days |
The other IPOs expected
| Company | Price |
|---|---|
| $19 to $21 | |
| $15 to $17 | |
| $15 to $17 | |
| $7 | |
| $5 to $7 |
Nodthera IPO questions
When is Nodthera's IPO?
Filed Oct 21, 2026 (Form S-1). No terms yet. Applied to list on Nasdaq as RZRA.
What is Nodthera's IPO price?
Nodthera has not set a price range yet; its Form S-1 of Oct 21, 2026 leaves it blank.
Who are the underwriters?
Jefferies, TD Cowen, Cantor, and Wedbush, as the prospectus's cover names them.
When does the lock-up end?
Its prospectus sets a lock-up of 180 days; the day it ends is read from its final prospectus once it lists.
Does Breakaway rate Nodthera?
Breakaway scores a new stock from its second trading day, ranked against every US stock it scores. For its first 21 sessions the page says New listing in place of the tier, and each check that needs more history waits for it.
Can Breakaway say where Nodthera's price will go?
No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Once Nodthera lists, Breakaway scores it against every US stock
- Its Quality Score from its second session, ranked against 3,191 stocks
- Every insider trade, the day it is filed
- The lock-up's end on your calendar, once the prospectus dates it
- An alert when its score is first set, and when it turns
See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.